nanobody-based CD19/CD22 tandem dual CAR-T
/ SenlangBio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 31, 2026
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
(clinicaltrials.gov)
- P1/2 | N=50 | Recruiting | Sponsor: Peking University People's Hospital | N=30 ➔ 50 | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2026
Enrollment change • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD22
1 to 1
Of
1
Go to page
1